Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Blueprint Medicines Corp (NQ: BPMC )

89.32 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Blueprint Medicines Corp

< Previous 1 2 3 4 5 6 Next >
Where Blueprint Medicines Stands With Analysts
Via Benzinga
Blueprint Medicines Highlights Detailed Data From Lead Product In Blood Cancer Patients
Via Benzinga
Roche Decides To Terminate Cancer Treatment Pact With Blueprint Medicines
Via Benzinga
Earnings Scheduled For February 16, 2023
Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year... 
Via Benzinga
Earnings Preview For Blueprint Medicines
Via Benzinga
FDA Slaps Partial Clinical Hold On Blueprint Medicines' Early-Stage Solid Tumor Study
Via Benzinga
Analyst Ratings for Blueprint Medicines
Via Benzinga
Blueprint Medicines's Return On Capital Employed Overview
According to data from Benzinga Pro, during Q3, Blueprint Medicines's (NASDAQ:BPMC) reported sales totaled $65.98 million. Despite a 16.62% increase in earnings, the company posted a loss of $133.16... 
Via Benzinga
9 Analysts Have This to Say About Blueprint Medicines
Within the last quarter, Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings: 
Via Benzinga
Recap: Blueprint Medicines Q3 Earnings
Blueprint Medicines (NASDAQ:BPMC) reported its Q3 earnings results on Tuesday, November 1, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Where Blueprint Medicines Stands With Analysts
Analysts have provided the following ratings for Blueprint Medicines (NASDAQ:BPMC) within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
Via Benzinga
Where Blueprint Medicines Stands With Analysts
Via Benzinga
Blueprint Medicines' Ayvakit 'Will Garner Approval' Despite Questions, This Analyst Says
Via Benzinga
Blueprint Medicines Stock Gets Price Target Cut Amid Lower Than Expected Ayvakit Uptake
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022
Upgrades 
Via Benzinga
Uber To Rally Around 82%? Here Are 5 Other Price Target Changes For Wednesday
Needham raised Uber Technologies, Inc. (NYSE: UBER) price target from $52 to $54. Needham analyst Bernie McTernan maintained the stock with a Buy rating. Uber shares fell 0.3% to $29.65 in pre-market... 
Via Benzinga
Analyst Sees Deteriorated Treatment Effect Of Blueprint's Much Awaited Mastocytosis Data
Via Benzinga
Data From Blueprint Medicines' Blood Disorder Trial Fails To Lift Shares
Blueprint Medicines Corporation (NASDAQ: BPMC)  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2022
Upgrades For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral to Buy. The current stock performance of Iris Energy shows a 52-week-high of $17.97 and a 52-week-low... 
Via Benzinga
What 14 Analyst Ratings Have To Say About Blueprint Medicines
Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Why GigaCloud Technology Jumped 206%; Here Are 79 Biggest Movers From Yesterday
Gainers GigaCloud Technology Inc (NASDAQ: GCT) shares jumped 206% to close at $48.01 on Friday on continued volatility following the company's IPO on Thursday. 
Via Benzinga
This Healthcare Stock Dipped Over 30%; Here Are 83 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Sanofi, Children's Place And Some Other Big Stocks Moving Lower On Wednesday
  Embark Technology, Inc. (NASDAQ: EMBK) fell 25.1% to $12.40. Embark Technology reported the completion of reverse stock split. 
Via Benzinga
Why Blue Water Vaccines Is Trading Higher By Around 80%, Here Are 61 Stocks Moving In Wednesday's Mid-Day Session
Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 79.5% to $4.57 after the company announced it plans to explore the potential development of a novel monkeypox vaccine using its norovirus... 
Via Benzinga
U.S. Stocks Open Lower; Nasdaq Down 150 Points
U.S. stocks traded lower this morning, with the Nasdaq composite dropping more than 150 points on Wednesday. 
Via Benzinga
Blueprint Medicines Stock Is Getting Hammered Wednesday: What's Happening?
Blueprint Medicines Corp (NASDAQ: BPMC) shares are trading lower by 22.2% to $53.32 Wednesday morning after the company announced top-line results from the registrational Part 2 of the PIONEER clinical... 
Via Benzinga
Blueprint Medicines Stock Hammered As 'Long-Awaited' Test Results Disappoint
Blueprint Medicines met all its goals, but the results paled from an earlier study. 
Via Investor's Business Daily
Blueprint Medicines Shares Fall After Topline Results From Late-Stage Neoplastic Disorder Study
Blueprint Medicines (NASDAQ: BPMC) announced positive top-line results from the Part 2 of PIONEER clinical trial of AYVAKIT (avapritinib) in patients with non-advanced systemic mastocytosis (SM). 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.